EMERGE are delighted to be leading the RAPID-CTCA trial with the Edinburgh Clinical Trials Unit (ECTU). This is a pragmatic study aiming to recruit 2,500 adult patients admitted with suspected or confirmed Acute Coronary Syndrome.
The study is taking place throughout the UK and we are still enlisting new sites. Recruitment will run for 30 months beginning March 2015.
This website provides some key information and contacts for participating sites, including recruitment figures and is a source of information for medical professionals who may be interested in the trial.
This is a synopsis of the RAPID-CTCA trial based upon the current version of the trial Protocol, version 4, 23-May-2016, which may be subject to change.
The trial aims to evaluate role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome.
The trial is funded by the NIHR HTA. The trial has been adopted onto the NIHR portfolio and therefore is eligible to receive CRN support.
Open parallel group randomised controlled trial of early computed tomography coronary angiography (CTCA) in patients presenting with suspected/confirmed acute coronary syndrome (ACS) to Emergency Departments (ED) and Medical Assessment Units.
~30 EDs, acute medical services, radiology and cardiology departments in tertiary/district general NHS hospitals.
Patients with suspected or confirmed ACS
Health technologies being assessed:
Early use of ≥64-slice CTCA as part of routine assessment compared to standard care.
The primary end-point will be all-cause death or recurrent non-fatal type 1 or type 4b MI at one year and time to first such event.
Royal Infirmary of Edinburgh – Professor Alasdair Gray
Sheffield Teaching Hospitals Trust – Professor Steve Goodacre
Derriford Hospital, Plymouth – Professor Carl Roobottom and Surgeon Captain Jason Smith
Torbay Hospital, Torquay – Dr Dirk Felmeden
Victoria Hospital, Kirkcaldy – Dr Andy Kinnon
Royal Berkshire Hospital, Reading – Dr Liza Keating
Russells Hall, Hospital, Dudley – Dr Robert Huggett
Royal Bournemouth & Christchurch Hospitals – Dr Jehangir Din
Borders General Hospital – Dr Anne Scott
Royal Victoria Infirmary, Newcastle – Dr Anna Beattie
Lewisham Hospital – Dr Khaled Alfakih
Jersey General Hospital – Dr Andrew Mitchell
Bradford Teaching Hospital – Dr Sudantha Bulugahapitiya
Glasgow Royal Infirmary – Dr Adrian Brady and Dr David Lowe
Sandwell Hospital – Dr Derek Connolly
Rotherham NHS Trust – Dr Rangasamy Muthusamy
Milton Keynes Hospital – Dr Atilla Kardos and Dr. John Northfield
University Hospital Southampton – Professor Nick Curzen
Royal Stoke University Hospital – Dr Hefin Jones
East Surrey Hospital – Dr Ansuman Saha
Guys & St Thomas NHS Foundation Trust – Dr Ronak Rajani
Luton & Dunstable Hospital – Dr Christopher Travill
Leeds Teaching Hospitals NHS Trust – Dr Saif-El-Dean Abdel-Rahman
Worcestershire Acute Hospitals NHS Trust – Dr Will Roberts
Queen Elizabeth Hospital, Birmingham – Dr Ben Holloway
Royal London Hospital – Professor Tim Harris
Whipps Cross Hospital – Professor Tim Harris
Ninewells Hospital – Dr John Irving
University Hospital of North Tees – Dr Justin Carter
Queen Alexandra, Portsmouth – Dr Chris Vorweck
Wrexham Mealor Hospital – Dr Ash Basu
New Cross Hospital, Woverhampton – Dr Elsa McAlindon
Basildon and Thurrock University Hospital – Dr. Jason Dungu
University hospital of South Manchester – Dr. Matthias Schmitt
Ulster Hospital – Dr. Patrick Donnelly
Raigmore Hospital, Inverness – Dr. Jonathon Watt
Queen Elizabeth University Hospital, Glasgow – Dr. Claire Mcgroarty
Patient ≥18 years with symptoms mandating investigation for suspected or confirmed ACS with at least one of:
(NB troponin assays will vary from site to site; local laboratory reference standards will be used).
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)
The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme
Developing a bioresource for all emergency presentations
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax